“Mike is a true partner with perfect combination of great scientific insight and smart business sense. He helped ACD tremendously in both strategic and operational aspects of company development.”
Yuling Luo, President and Chief Executive Officer, Advanced Cell Diagnostics
Consultant, San Mateo, CA
Mike Dybbs joined New Leaf Venture Partners in 2009 and transitioned to become a consultant in 2016. He primarily focuses on biopharmaceutical investing. Prior to joining New Leaf, Mike was a Principal at the Boston Consulting Group where he was a core member of their Health Care practice. At BCG, Mike led projects in the biopharmaceutical industry across a range of functions and therapeutic areas. He also spent time as an independent consultant, working on spin-outs of early stage programs from companies and universities.
Mike graduated magna cum laude from Harvard University with an A.B. in biochemical sciences and received his PhD in molecular biology and genetics from UC Berkeley, where he was awarded a Howard Hughes Medical Institute fellowship. His research had been published in peer-reviewed journals, including Neuron, Science and Nature.
Board Seats and Investments
Notable Alumni Investments
Advanced Cell Diagnostics (Acquired by Bio-Techne)